Episode 2: A View On Manufacturing Inhaled Drug Products
A view on
by Lonza
2w ago
What If the Jab Were a Puff? A Look at Drug Delivery to the Lungs In this episode we explore the advantages of using inhalers for drug delivery with Lonza experts Kim Shepard and Matt Ferguson. In late 2022, China introduced the world’s first Covid-19 vaccine to be inhaled into the lungs. The Chinese scientists who developed the vaccine tout its ability to directly stimulate the immune system’s first line of defense – the lungs’ mucous membrane. However, vaccines are just the tip of the inhaler iceberg. While we all are familiar with metered-dose inhalers, as well as nebulizers, for asthma, a ..read more
Visit website
Episode 1: A View On Cell Culture Media
A view on
by Lonza
2M ago
Developing Cell Culture Media For Growing Cells We are back! And in the first episode of our new season, we explore growing cells for therapeutic purposes with Lonza specialists Alexis Bossie, Director of Media R&D, and Tariq Haq, Senior Director of Global Media Marketing.        Lab-grown meat is having a moment—the FDA just declared one company’s cultivated chicken safe to eat, and another type of lab poultry was just served for dinner to delegates at this year’s COP27 climate conference in Egypt. Whether this piques your pallet’s curiosity or turns you ..read more
Visit website
Episode 11: Season 2 Highlights
A view on
by Lonza
3M ago
Join us in celebrating the finale of our second season of A View On, the Lonza podcast. Over the past few months, we have brought you a series of insider conversations with our experts at Lonza, our partners, and leaders in the industry exploring the new pharma and biotechnology trends. We explored exciting topics, such as oncolytic viruses, the human microbiome, antibody-drug conjugates, nuances of early drug development, capsule manufacturing, and the use of artificial intelligence in the pharma industry. In the latest episode, the podcast host, Lonza’s Martina Ribar Hestericová, recaps the ..read more
Visit website
Episode 10: AI in the Pharma Industry
A view on
by Lonza
5M ago
Artificial Intelligence and Life Sciences: The Dawning of a Digital Revolution in Pharma Manufacturing Dr. Loubna Bouarfa, CEO of OKRA.ai, and Stephan Rosenberger, Lonza's Head of Digital Transformation, discuss how AI is currently transforming the pharma industry. Machine learning is an essential subset of the vast field of Artificial Intelligence, in which computer programs aim to mimic human intelligence. Machine learning is at work in many of the algorithms that impact our daily lives, from suggesting new songs we might like to targeting ads. These algorithms learn from large data sets sim ..read more
Visit website
Episode: De-risking Drug Development
A view on
by Lonza
6M ago
Where There’s A Risk, There’s A Way: De-risking Drug Development at the Earliest Stages Lonza’s wide array of analytical tools and professional experience create a go-to solution for small biotechs looking to decrease risk in their drug development process. An evolving toolbox of technology and advanced scientific knowledge is fueling the growth of a wide range of next-generation drugs in today’s pipelines. These novel but complex products, while offering the ability to treat previously unmet medical needs across the globe, also present many challenges. This is often due to their unique profil ..read more
Visit website
Episode 8: Colors of Capsules
A view on
by Lonza
7M ago
Capsule Manufacturing: It’s Not Only What’s Inside That Counts The recent EU ban on Titanium Dioxide and changing customer habits are shaking up capsule production. Over the past few years, the coloring and manufacturing of pill capsules have undergone significant changes due to new EU regulations and customer demand for natural ingredients. And while originally invented to mask and protect the contents inside a capsule, research suggests that the color of a tablet or pill can affect how patients feel about their medication. Until recently, manufacturers have primarily used Titanium Dioxide (T ..read more
Visit website
Episode 7: Antibody-Drug Conjugates
A view on
by Lonza
9M ago
Antibody-drug Conjugates: Next-Generation of Targeted Cancer Treatments Iwan Bertholjotti and Laurence Bonnafoux from Lonza give an insider look at how these promising treatments make it from development to commercialization. Chemotherapy is the first-line treatment for most types of cancer. However, one of the major challenges with this approach is that it targets both cancer and healthy cells, with patients suffering severe side effects. A new class of therapies, called antibody-drug conjugates, or ADCs, can target tumors much more precisely by harnessing the power of antibodies. The antibod ..read more
Visit website
Episode 6: Manufacturing of Exosomes
A view on
by Lonza
11M ago
Putting Manufacturing First: Codiak Moves Swiftly into Clinical Trials with Exosome-based Treatments  Sriram Sathyanarayanan, Codiak’s CSO, and Linda Bain, their CFO, share how the company moved into clinical trials in under 6 years.   Exosomes, extremely small vesicles shed by all cell types, promise to become a viable delivery system for treatments of many diseases. But until recently, manufacturing them at a commercially viable scale has been unfeasible. That is why in 2015 the company Codiak took a two-pronged approach to developing exosome-based treatments: prioritizing both the ..read more
Visit website
*Repost* Exosomes
A view on
by Lonza
11M ago
In this reposted episode from December 2020, we're exploring how a better understanding of exosomes is leading to new treatments and diagnostic technologies with Uwe Gottschalk.  According to Uwe , the exosome revolution is already in full march. As researchers begin to identify how these cell-generated, nano-sized delivery drones function in the human body, novel drug delivery prospects are emerging, including applications for cancer, neurodegenerative diseases and spinal cord injury recovery. Perhaps even more exciting is the role exosomes will play in diagnostic applications in the nea ..read more
Visit website
Episode 5: Importance of Immunogenicity
A view on
by Lonza
1y ago
De-risking Drug Development: Early Testing for Toxicity Saves Time and Resources   Yvette Stallwood, head of Lonza’s Early Development Services, talks about patient safety and other advantages of early testing for immunogenicity in the drug development pipeline.   In the high-stakes drug discovery game, from IND filings all the way up through the clinical trial phase, regulatory authorities are now expecting developers to have an immunogenicity risk strategy in place. “It really is essential that drug developers assess the immunogenicity risk as early as possible in the pipeline, as ..read more
Visit website

Follow A view on on Feedspot

Continue with Google
OR